Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.

Original publication

DOI

10.1038/nm1698

Type

Journal article

Journal

Nat Med

Publication Date

01/2008

Volume

14

Pages

25 - 27

Keywords

Animals, Antibodies, Monoclonal, Epitopes, Hepacivirus, Hepatitis Antibodies, Hepatitis C, Humans, Immunoglobulin G, Mice, Neutralization Tests, Rats, Species Specificity, Viral Hepatitis Vaccines